Acquired by AstraZeneca
Therapeutics for respiratory diseases. Spin out of technology from Nektar.
Redwood City, CA
Therapeutics for respiratory diseases. Spin out of technology from Nektar.
Redwood City, CA
Location: United States, California, Redwood City
Employees: 51-200
Total raised: $149M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.11.2012 | Series D | $65M | - |
| 19.10.2010 | Series C | $69M | - |
| 01.02.2010 | - | $15M | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.11.2012 | California pharma start-up targeting COPD & asthma using inhalers raises $65M | The money will be used to start a Phase 3 clinical trial for PT003, the company’s lead candidate to treat COPD. “Through our comprehensive Phase 2 program, Pearl has characterized the dose response, minimally effective dose and optimal dose... |
| 13.11.2012 | Pearl Therapeutics Raises $65M Series D | REDWOOD CITY, CA, 5AM Ventures, Clarus Ventures and New Leaf Venture Partners participated in the Series D round, which was led by Vatera Healthcare Partners. >> Click here for more funding data on Pearl Therapeutics >> To e... |
| 13.11.2012 | Google, Platfora, DataSift: Bay Area Venture News by the Numbers | Share Share on Facebook Share on Twitter LinkedIn Email Reprints We don’t try to cook up stories on every Series A, B, C, or D round raised by Bay Area startups. But there seemed to be an extra helping of fundraising deals and other venture... |
| 13.11.2012 | Pearl Therapeutics Raises $65M in Series D Financing | Pearl Therapeutics Inc., a Redwood City, CA-based biopharmaceuticals company, has raised $65m in Series D financing. The round was led by Vatera Healthcare Partners, with participation from existing investors 5AM Ventures, Clarus Ventures a... |
| 13.11.2012 | PEARL THERAPEUTICS RAISES $65 MILLION SERIES D TO START PT003 PHASE 3 | - |
| 03.12.2010 | Pearl Therapeutics Beats $3B Lung Drug, Anacor’s Flat IPO, Medtronic Buys Ardian for $800M, & More Bay Area Life Sciences News | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Thanksgiving got in the way of last week’s biotech roundup, so this week I’m reaching a little further back in the archive for stories you may have missed. —Redwood City, CA-b... |
| 19.10.2010 | Pearl Therapeutics Closes $69M Series C Financing | Pearl Therapeutics Inc., a Redwood City, CA-based company that develops clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COP... |
| 19.10.2010 | PEARL THERAPEUTICS RAISES $69 MILLION SERIES C FINANCING | - |
| 01.02.2010 | PEARL THERAPEUTICS RAISES $15 MILLION TO ADVANCE PT003, LAMA/LABA COMBINATION BRONCHODILATOR FOR COPD, INTO PHASE 2B STUDY | - |
| 01.02.2010 | Pearl Therapeutics Raises $15M Financing | Pearl Therapeutics Inc., a Redwood City, CA-based developer of therapies for the treatment of chronic respiratory diseases, announced a $15m financing from existing investors Clarus Ventures, New Leaf Venture Partners and 5AM Ventures. The ... |
Show more